Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trisha Wise-Draper

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective StudyRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
The Journal of Clinical Investigation|May 19, 2026
Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancerRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Cell Reports. Medicine|March 5, 2024
Beta-defensin index: A functional biomarker for oral cancer detectionSantosh K Ghosh, Yuncheng Man, Arwa Fraiwan, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
Lancet Regional Health. Americas|March 24, 2025
Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infectionEmily Pei-Ying Lin, Chih-Yuan Hsu, Sanjay Mishra, et al.
BMC Cancer|March 23, 2023
Impact of COVID-19 in patients on active melanoma therapy and with history of melanomaDouglas B Johnson, Michael B Atkins, Cassandra Hennessy, et al.
Nature Cell Biology|August 3, 2019
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastomaSatoshi Kofuji, Akiyoshi Hirayama, Alexander Otto Eberhardt, et al.
Translational Oncology|June 11, 2023
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular diseaseMelissa Y Y Moey, Cassandra Hennessy, Benjamin French, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective StudyRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
The Journal of Clinical Investigation|May 19, 2026
Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancerRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Cell Reports. Medicine|March 5, 2024
Beta-defensin index: A functional biomarker for oral cancer detectionSantosh K Ghosh, Yuncheng Man, Arwa Fraiwan, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
Lancet Regional Health. Americas|March 24, 2025
Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infectionEmily Pei-Ying Lin, Chih-Yuan Hsu, Sanjay Mishra, et al.
BMC Cancer|March 23, 2023
Impact of COVID-19 in patients on active melanoma therapy and with history of melanomaDouglas B Johnson, Michael B Atkins, Cassandra Hennessy, et al.
Nature Cell Biology|August 3, 2019
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastomaSatoshi Kofuji, Akiyoshi Hirayama, Alexander Otto Eberhardt, et al.
Translational Oncology|June 11, 2023
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular diseaseMelissa Y Y Moey, Cassandra Hennessy, Benjamin French, et al.
Pageof 4